Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

被引：0
|
作者：
Jamaal L. James
Justin M. Balko
机构：
[1] Vanderbilt University Medical Center,Department of Medicine
[2] Vanderbilt University Medical Center,Cancer Biology Program
[3] Vanderbilt University Medical Center,Department of Pathology, Microbiology and Immunology
[4] Vanderbilt University Medical Center,Breast Cancer Research Program
来源：
Current Breast Cancer Reports | 2019年 / 11卷
关键词：
Breast cancer; Biomarkers; Programmed death-ligand 1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：217 / 227
页数：10
相关论文
共 50 条
  • [1] Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
    James, Jamaal L.
    Balko, Justin M.
    CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 217 - 227
  • [2] Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
    Rizzo, Alessandro
    Ricci, Angela Dalia
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) : 549 - 555
  • [3] Biomarkers of immunotherapy response in breast cancer beyond PD-L1
    Chic, Nuria
    Braso-Maristany, Fara
    Prat, Aleix
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 39 - 49
  • [4] Biomarkers of immunotherapy response in breast cancer beyond PD-L1
    Nuria Chic
    Fara Brasó-Maristany
    Aleix Prat
    Breast Cancer Research and Treatment, 2022, 191 : 39 - 49
  • [5] PD-L1 as a Biomarker in Gastric Cancer Immunotherapy
    Cho, Yunjoo
    Ahn, Soomin
    Kim, Kyoung-Mee
    JOURNAL OF GASTRIC CANCER, 2025, 25 (01) : 177 - 191
  • [6] Refining patient selection for breast cancer immunotherapy: beyond PD-L1
    Kossai, M.
    Radosevic-Robin, N.
    Penault-Llorca, F.
    ESMO OPEN, 2021, 6 (05)
  • [7] Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
    Nunez Abad, Martin
    Calabuig-Farinas, Silvia
    Lobo de Mena, Miriam
    Torres-Martinez, Susana
    Garcia Gonzalez, Clara
    Garcia Garcia, Jose Angel
    Iranzo Gonzalez-Cruz, Vega
    Camps Herrero, Carlos
    CANCERS, 2022, 14 (02)
  • [8] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
    Patel, Sandip Pravin
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (04) : 847 - 856
  • [9] Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
    Chretien, Sebastian
    Zerdes, Ioannis
    Bergh, Jonas
    Matikas, Alexios
    Foukakis, Theodoros
    CANCERS, 2019, 11 (05)
  • [10] Beyond PD-L1 Markers for Lung Cancer Immunotherapy
    Wojas-Krawczyk, Kamila
    Kalinka, Ewa
    Grenda, Anna
    Krawczyk, Pawel
    Milanowski, Janusz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (08)
12345